Title:Peroxiredoxin-6: A Guardian of Lung Pathophysiologies
Volume: 22
Issue: 9
Author(s): Anju Kumari, Rimpy Kaur Chowhan, Pushpa Kakchingtabam, Sharifun Shahnaj, Hamidur Rahaman, Mohd Saquib Ansari and Laishram Rajendrakumar Singh*
Affiliation:
- Dr. B.R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi,India
Keywords:
Peroxiredoxin-6 , reactive oxygen species (ROS) , antioxidants , hyperoxia , acute lung injury , pulmonary microvascular endothelial cells (PMVEC) .
Abstract: The moonlighting protein, Prdx-6, exhibits peroxidase activity, phospholipase activity,
and lysophosphatidylcholine acyltransferase (LPCAT) activity. Although it is ubiquitous in expression,
its level is prominently high in the lung. Prdx-6 has been known to be an important enzyme
for the maintenance of normal lung physiologies including, anti-oxidant defense, lung surfactant
homeostasis, and cell signaling. Studies further unveiled that the altered activity (peroxidase or ai-
PLA2) of this enzyme is linked with various lung pathologies or diseases. In the present article, we
attempted to address the various pathophysiologies or disease conditions (like lung ischemia, hyperoxia,
lung cancer, emphysema, and acute lung injury) wherein Prdx-6 is involved. The study implicates
that Prdx-6 could be used as a common drug target for multiple lung diseases. Important future
insights have also been incorporated.
